Melanie Sena

DSM Pharmaceuticals appoints a new business unit director of its DSM Biologics/BioSolutions businesses.

DSM Pharmaceutical Products opens a cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.

Novartis files Citizen Petition with FDA to maintain naming policy for all biologics to help ensure patient safety.

PhRMA reports 452 new medicines are in development for rare diseases, including genetic disorders, neurological conditions, infectious diseases, and autoimmune disorders.

Governor Jerry Brown cites physician notification requirements for dispensing biosimilars as premature in the absence of FDA specifications for interchangeability.

ABC Laboratories plans to move operations of its subsidiary, Morse Laboratories, based in California, to Missouri.

Soligenix has been awarded a multimillion BARDA contract for the advanced preclinical and manufacturing development of OrbeShield, a treatment for gastrointestinal acute radiation syndrome.

CHMP recommended 11 new medicines for approval, the most approval recommendations at a CHMP meeting thus far in 2013.

The CMDh agrees to suspend the marketing authorization of Numeta G13%E because of a risk of hypermagnesaemia.

CEO of Waters Corporation will retire within in the next two years.